Masato Shiba Selected Research

Tenascin

1/2020	Tenascin-C in brain injuries and edema after subarachnoid hemorrhage: Findings from basic and clinical studies.
1/2020	Toll-Like Receptor 4 and Tenascin-C Signaling in Cerebral Vasospasm and Brain Injuries After Subarachnoid Hemorrhage.
1/2020	Link Between Receptors That Engage in Developing Vasospasm After Subarachnoid Hemorrhage in Mice.
2/2019	Lessons from tenascin-C knockout mice and potential clinical application to subarachnoid hemorrhage.
1/2019	Dose-Dependent Inhibitory Effects of Cilostazol on Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage.
1/2018	Effects of Tenascin-C Knockout on Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage in Mice.
6/2016	Deficiency of tenascin-C and attenuation of blood-brain barrier disruption following experimental subarachnoid hemorrhage in mice.
1/2016	Epidermal growth factor-like repeats of tenascin-C-induced constriction of cerebral arteries via activation of epidermal growth factor receptors in rats.
1/2016	The Role of Matricellular Proteins in Brain Edema after Subarachnoid Hemorrhage.
1/2015	Tenascin-C is a possible mediator between initial brain injury and vasospasm-related and -unrelated delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masato Shiba Research Topics

Disease

24	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 10/2021 - 10/2011
12	Intracranial Vasospasm 01/2020 - 10/2011
8	Brain Injuries (Brain Injury) 01/2020 - 04/2014
4	Brain Edema (Cerebral Edema) 01/2020 - 01/2016
3	Carotid Stenosis (Carotid Artery Stenosis) 07/2021 - 08/2017
3	Cerebral Infarction 01/2020 - 01/2018
3	Brain Ischemia (Cerebral Ischemia) 01/2019 - 01/2015
3	Aneurysm (Aneurysms) 01/2018 - 05/2017
3	Body Weight (Weight, Body) 01/2015 - 04/2012
2	Hydrocephalus (Hydrocephaly) 10/2021 - 01/2018
2	Cysts 10/2020 - 01/2010
2	Intracranial Aneurysm (Cerebral Aneurysm) 01/2020 - 05/2017
2	Inflammation (Inflammations) 01/2020 - 01/2018
2	Muscle Spasticity (Spastic) 01/2020 - 04/2012
2	Neoplasms (Cancer) 01/2020 - 07/2019
2	Rupture 01/2020 - 05/2017
1	Thrombosis (Thrombus) 10/2022
1	Ischemic Stroke 10/2022
1	Atrophy 04/2022
1	Wounds and Injuries (Trauma) 10/2021
1	Pathologic Constriction (Stenosis) 07/2021
1	Ischemia 02/2021
1	Spinal Cord Diseases 01/2021
1	Postpartum Hemorrhage 01/2021
1	Dermoid Cyst (Dermoid) 10/2020
1	Glioma (Gliomas) 01/2020
1	Heart Arrest (Cardiac Arrest) 01/2020
1	Status Epilepticus (Complex Partial Status Epilepticus) 01/2020
1	Bradycardia 01/2020
1	Hypoxia (Hypoxemia) 01/2020
1	Sepsis (Septicemia) 01/2020
1	Neuroinflammatory Diseases 01/2020
1	Edema (Dropsy) 01/2020
1	Embolism (Embolus) 01/2019
1	Infarction (Infarctions) 01/2018
1	Hypertriglyceridemia 08/2017
1	Dyslipidemias (Dyslipidemia) 08/2017
1	Pain (Aches) 12/2016
1	Hypesthesia (Numbness) 12/2016
1	Herpes Zoster 06/2016
1	Amyloidosis 01/2016
1	Type 2 Diabetes Mellitus (MODY) 01/2016
1	Familial Hypophosphatemic Rickets (X-Linked Hypophosphatemia) 02/2015

Drug/Important Bio-Agent (IBA)

18	Proteins (Proteins, Gene)FDA Link 10/2021 - 04/2012
17	TenascinIBA 01/2020 - 10/2011
4	OsteopontinIBA 10/2021 - 01/2013
4	Imatinib Mesylate (Gleevec)FDA Link 01/2015 - 04/2012
3	Mitogen-Activated Protein KinasesIBA 01/2020 - 04/2012
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 04/2014 - 04/2012
2	LDL CholesterolIBA 07/2021 - 08/2017
2	Glucose (Dextrose)FDA LinkGeneric 07/2021 - 01/2014
2	oxidized low density lipoproteinIBA 07/2021 - 08/2017
2	Triglycerides (Triacylglycerol)IBA 07/2021 - 08/2017
2	ErbB Receptors (EGF Receptor)IBA 01/2020 - 07/2019
2	Cilostazol (Pletal)FDA LinkGeneric 01/2020 - 01/2019
2	LigandsIBA 01/2020 - 01/2020
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2020 - 01/2019
2	CaspasesIBA 01/2020 - 04/2014
2	Galectin 3 (LGALS3)IBA 01/2020 - 01/2018
2	Toll-Like Receptor 4IBA 01/2020 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 10/2011
2	Indicators and Reagents (Reagents)IBA 01/2018 - 05/2017
2	Tyrosine (L-Tyrosine)FDA Link 01/2013 - 04/2012
2	Phosphotransferases (Kinase)IBA 01/2013 - 04/2012
2	Platelet-Derived Growth FactorIBA 01/2013 - 04/2012
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 07/2021
1	Glutamic Acid (Glutamate)FDA Link 02/2021
1	Ethanol (Ethyl Alcohol)IBA 10/2020
1	Fibrinogen (Factor I)FDA Link 01/2020
1	Heme (Haem)IBA 01/2020
1	SteroidsIBA 01/2020
1	NF-kappa B (NF-kB)IBA 01/2020
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 07/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2019
1	Hemoglobins (Hemoglobin)IBA 01/2019
1	PeriostinIBA 01/2019
1	Therapeutic UsesIBA 10/2017
1	Eosine Yellowish-(YS) (Eosin)IBA 05/2017
1	Hematoxylin (Haematoxylon)IBA 05/2017
1	Hemostatics (Antihemorrhagics)IBA 05/2017
1	Evans Blue (Blue, Evans)FDA Link 06/2016
1	Phosphates (Orthophosphate)IBA 06/2016
1	Matrix Metalloproteinases (MMPs)IBA 06/2016
1	Coloring Agents (Dyes)IBA 06/2016
1	Insulin (Novolin)FDA Link 01/2016
1	Extracellular Matrix ProteinsIBA 01/2016
1	UridineIBA 01/2015

Therapy/Procedure

4	Therapeutics 01/2021 - 06/2016
2	Catheters 10/2022 - 12/2020
2	Stents 10/2022 - 12/2020
2	Decompression 01/2020 - 12/2016
1	Thrombectomy 10/2022
1	Debridement 04/2022
1	Carotid Endarterectomy 07/2021
1	Ventriculoperitoneal Shunt 01/2021
1	Sclerotherapy 10/2020
1	Artificial Respiration (Mechanical Ventilation) 01/2020
1	Chemoradiotherapy 01/2020
1	Endarterectomy (Thromboendarterectomy) 08/2017
1	Laminoplasty 02/2015